Last reviewed · How we verify
FYU-981
FYU-981 is an investigational therapeutic agent in phase 3 development by Fuji Yakuhin Co., Ltd.
At a glance
| Generic name | FYU-981 |
|---|---|
| Also known as | Final formulation of FYU-981 |
| Sponsor | Fuji Yakuhin Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited publicly available information exists regarding the specific mechanism of action for FYU-981. As a phase 3 candidate from Fuji Yakuhin, it represents an advanced-stage investigational compound, but detailed mechanistic data has not been widely disclosed in accessible literature.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout (PHASE3)
- A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants (PHASE1)
- Drug-drug Interaction Study of FYU-981 and Oxaprozin (PHASE1)
- Study of FYU-981 in Hyperuricemia With or Without Gout (PHASE3)
- Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout (PHASE3)
- Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout (PHASE3)
- Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types) (PHASE1)
- Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FYU-981 CI brief — competitive landscape report
- FYU-981 updates RSS · CI watch RSS
- Fuji Yakuhin Co., Ltd. portfolio CI